Baseline patient characteristics in CD8 T cell cohort
| CD | UC | |||||
| IBD1 (n=33) | IBD2 (n=33) | P value | IBD1 (n=24) | IBD2 (n=28) | P value | |
| Age (years) | 30.3 (25.3–36.1) | 30.3 (23.2–38.7) | 0.98 | 43.8 (30.9–50.4) | 40.5 (29.1–54.0) | 0.92 |
| Gender (% male) | 14 (42.4%) | 13 (39.4%) | 1.00 | 13 (54.2%) | 13 (46.4%) | 0.78 |
| Current smoker | 10 (28.6%) | 12 (33.3%) | 0.79 | 1 (4.2%) | 0 (0%) | 0.46 |
| Newly diagnosed | 27 (81.8%) | 24 (72.7%) | 0.56 | 15 (62.5%) | 20 (71.4%) | 0.56 |
| Disease duration (years) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.78 | 0.0 (0.0–2.2) | 0.0 (0.0–3.6) | 0.76 |
| Haemoglobin (g/L) | 12.5 (11.7–13.3) | 13.1 (11.8–13.6) | 0.63 | 14.0 (12.8–14.4) | 13.0 (12.3–14.6) | 0.26 |
| CRP (mg/L) | 26 (16–39) | 25 (10–59) | 0.60 | 6 (3–23) | 4 (2–21) | 0.26 |
| Albumin (g/L) | 35 (32–37) | 37 (34–39) | 0.14 | 39 (37–41) | 39 (37–41) | 0.96 |
| Disease distribution: | ||||||
| CD – L1 (ileal) | 9 (27.3%) | 13 (39.4%) | 0.43 | – | – | – |
| CD – L2 (ileocolonic) | 11 (33.3%) | 9 (27.3%) | 0.79 | – | – | – |
| CD – L3 (colonic) | 13 (39.4%) | 11 (33.3%) | 0.80 | – | – | – |
| CD – L4 (upper GI) | 2 (6.1%) | 3 (9.1%) | 1.00 | – | – | – |
| Perianal | 6 (18.2%) | 3 (9.1%) | 0.48 | – | – | – |
| UC – E1 (proctitis) | – | – | – | 5 (20.8%) | 8 (28.6%) | 0.75 |
| UC – E2 (left sided) | – | – | – | 9 (37.5%) | 11 (39.3%) | 1.00 |
| UC – E3 (extensive) | – | – | – | 10 (41.7%) | 9 (32.1%) | 0.57 |
| Prospective follow-up (years) | 4.9 (3.6–7.4) | 5.3 (4.3–8.3) | 0.24 | 5.6 (3.6–7.1) | 5.5 (2.4–8.4) | 0.54 |
Data shown in parentheses indicate median (IQR) for continuous variables or percentages for dichotomous variables. Statistical significance was calculated using a Mann-Whitney test (two tailed) for continuous variables and Fisher’s exact test (two tailed) for dichotomous variables. Disease distribution was classified according to the Montreal Classification.27
CD, Crohn’s disease; CRP, C reactive protein.